Global Treatment-Resistant Depression Treatment Market Is Expected To Expand To Reach US$ 1,389.3 Mn

The latest market report published by Credence Research, Inc. “Global Treatment-Resistant Depression Treatment Market – Growth, Future Prospects, Competitive Analysis, 2019- 2027,” the global treatment-resistant depression treatment market is set to reach from US$ 1,010.6 Mn in 2018 to US$ 1,389.3 Mn  in 2027 expanding at a CAGR of 3.6% from 2019 to 2027.

Browse the full report Treatment-Resistant Depression Treatment Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at

Market Insights

Depression if untreated at an early stage may prove fatal often resulting in suicidal tendency in ailing patients. According to the statistics provided by World Health Organization (WHO), each year 800,000 people die due to suicide. It is important for physicians to perform accurate diagnosis and identify cormorbid symptoms to confirm treatment resistant depression in ailing patients.

Depression is the most common clinical manifestation of mental disorder. As per the research citings of World Health Organization (WHO) approximately 300 million people suffer with depression worldwide. It is noteworthy that one third of the patients suffering with depression show resistance to medicines the exact etiology behind this resistance is unknown. The medicines opted for its treatment are MAOI’s, SSRI’s tricyclic antidepressant etc. Exact diagnosis is important for the treatment of TRD. The treatment regime consists of prescribing antidepressant to its maximum tolerable dose, combination of antidepressants, switching to atypical antidepressants etc. Recent approval of Spravato (Esketamine nasal sprays) will accelerate its market demand for treating TRD. Strong drug pipeline will propel the market growth during the forecast period.

North America is presently accountable for 34.2% market share and is the dominating regional segment for TRD treatment market. According to the latest statistical reports presented by Center for Disease Control and Prevention (CDC), in the United States the incidence rate of suicidal deaths is 14.5 per 100,000 people. Significant rise in stress and drug abuse has lead to significant rise in the number of ailing patients showing resistance to medications employed in treatment for depression. Domicile of key players such as Pfizer, Inc., Eli Lilly & Company and Mylan Laboratories, Inc., further propel the market growth in the region. Europe is in the second position holding 30.5% market share primarily due to affordable reimbursement scenario for the drugs employed in the treatment of TRD. Asia Pacific is representing 17.3% market share on account of rising prevalence of mental disorders and effective implementation of treatment regimen pertaining to treat depression and suicidal tendency across all age groups.

Pharmaceutical companies manufacturing drugs for the treatment regimen of treatment-resistant depression are Bristol Myers Squibb Company, Eli Lilly & Company, Janssen Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Valeant Pharmaceuticals International, Validus Pharmaceuticals LLC and Wyeth.

Key Market Movements:

  • Rising prevalence of treatment resistant depression throughout the globe
  • Recent approval by Spravato by USFDA and strong product pipeline will provide good momentum for TRD treatment market in the near future
  • Affordable reimbursement scenario for medicines employed in treating TRD